Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: A randomized controlled trial

Contraception

Volumn 85, Issue 6, 2012, Pages 595-601

  Archer, David F ^a   Stanczyk, Frank Z ^b   Rubin, Arkady ^c   Foegh, Marie ^c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Agile Therapeutics   (United States)

Author keywords

AG200 15; Ethinyl estradiol; Levonorgestrel; Transdermal contraceptive delivery system

Indexed keywords

CONTRACEPTIVE AGENT; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORGESTIMATE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADULT; CONTRACEPTIVE AGENTS, FEMALE; CROSS-OVER STUDIES; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL;

EID: 84860539386     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2011.10.006     Document Type: Article

References (16)

1. D.F. Archer, V. Cullins, G.W. Creasy, and A.C. Fisher The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy Contraception 69 2004 189 195 (Pubitemid 38224216)
2. D.F. Archer, A. Bigrigg, G.H. Smallwood, G.A. Shangold, G.W. Creasy, and A.C. Fisher Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women Fertil Steril 77 2 Suppl 2 2002 S27 S31
3. W. Urdl, D. Apter, and A. Alperstein Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception Eur J Obstet Gynecol Reprod Biol 121 2005 202 210 (Pubitemid 41074094)
4. M.W. van den Heuvel, A.J.M. van Bragt, A.K.M. Alnabawy, and M.C.J. Kaptein Comparison of ethinyl estradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive Contraception 72 2005 168 174 (Pubitemid 41133355)
5. D. Devineni, D. Skee, and N. Vaccaro Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive J Clin Pharmacol 47 2007 497 509 (Pubitemid 46465957)
6. Ortho Evra® [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2008.
7. J.A. Cole, H. Norman, M. Doherty, and A.M. Walker Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users Obstet Gynecol 109 2007 339 346 (Pubitemid 46197426)
8. F.Z. Stanczyk, A. Rubin, L. Flood, and M. Foegh Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinyl estradiol and levonorgestrel Horm Mol Biol Clin Investig 6 2011 231 240
9. L.S. Abrams, D.M. Skee, F.A. Wong, N.J. Anderson, and P.T. Leese Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches J Clin Pharmacol 41 2001 1232 1237 (Pubitemid 32983222)
10. H. Licea-Perez, S. Wang, C.L. Bowen, and E. Yang A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 852 2007 69 76 (Pubitemid 46839209)
11. J. Spona, W. Feichtinger, C. Kindermann, C. Wünsch, and K. Brill Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol Contraception 54 1996 299 304 (Pubitemid 26386740)
12. Seasonique® NDA. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2006/021840s000-ClinPharmR.pdf. Retrieved November 30, 2010.
13. Levlite® NDA. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/98/20860-statr-clinpharmr.pdf. Retrieved November 30, 2010.
14. J. Endrikat, H. Blode, C. Gerlinger, P. Rosenbaum, and W. Kuhnz A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel Eur J Contracept Reprod Health Care 7 2002 79 90 (Pubitemid 34848343)
15. H. Blode, W. Wuttke, W. Loock, G. Röll, and R. Heithecker A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers Eur J Contracept Reprod Health Care 5 2000 256 264 (Pubitemid 32165464)
16. W. Kuhnz, G. al-Yacoub, and A. Fuhrmeister Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation Contraception 46 1992 455 469